On September 2, 2020 Kadmon Holdings, Inc. (NYSE:KDMN) reported that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual investor conferences (Press release, Kadmon, SEP 2, 2020, View Source [SID1234564325]):
H.C. Wainwright 22nd Annual Global Investment Conference

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Monday, September 14, 2020
Time: 11:00 a.m. ET
Cantor Fitzgerald Virtual Global Healthcare Conference

Date: Tuesday, September 15, 2020
Time: 1:20 p.m. ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Date: Monday, September 21, 2020
Time: 2:30 p.m. ET
Harlan Waksal will participate and host virtual investor meetings during the following investor conferences:

Citi 15th Annual BioPharma Conference

Dates: Wednesday, September 9, 2020 and Thursday, September 10, 2020

Morgan Stanley Virtual Global Healthcare Conference

Date: Thursday, September 17, 2020

Live audio webcasts of the presentations may be accessed on the Investors section of the Kadmon website at www.kadmon.com. Replays of the webcasts will be available for 90 days.

On September 2, 2020 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences (Press release, Harpoon Therapeutics, SEP 2, 2020, View Source [SID1234564324]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 3:45 p.m. ET / 12:45 p.m. PT; and

A "Novel Antibodies and Protein Therapeutics in Oncology" panel at Citi’s 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 10:45 a.m. ET / 7:45 a.m. PT.
A live audio webcast of the fireside chat at the Baird conference will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com with an archived replay available following the event.

On September 2, 2020 Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, reported it has been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat’s gp96 platform in combination with a T cell costimulatory agonist in a single therapy (Press release, Heat Biologics, SEP 2, 2020, View Source [SID1234564323]). This newly issued US patent compliments Heat’s growing patent estate on this platform technology, which also includes US Patent No. 10,046,047, with claims to compositions of matter covering Heat’s gp96 platform in combination with OX40L, a T cell costimulatory agonist.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pre-clinical studies combining Heat’s secreted gp96 plus OX40L T cell co-stimulator in a single therapy, administered locally, have demonstrated superior activity in preclinical studies compared to gp96 in combination with conventional OX40 antibody administered systemically by IV infusion. Additional potential advantages of this novel combination approach include enhanced memory T cell response, limited systemic toxicity and cost advantages compared to multiple systemic therapies.

Jeff Wolf, Chief Executive Officer of Heat, commented, "This newly issued patent represents a potential breakthrough in combination drug development. Current combination approaches under development hold significant promise but also face meaningful challenges such as systemic toxicity and a lack of measurable synergistic effect. In contrast, we have developed a unique approach, combining the strengths of our gp96 platform (including antigen presentation, T cell activation, and TLR activation) with an immune booster (providing, for instance, localized T cell co-stimulation) in a single therapy. We believe this combination therapy holds enormous promise in the treatment of cancer and infectious diseases, potentially including COVID-19."

"Specifically, our preclinical studies have demonstrated more pronounced CD8+ T cell prime and memory response; increased antigen specificity; no off-target systemic inflammatory cytokines; greater anti-tumor immunity; and increased overall survival. Our Phase 1 trials with gp96 (HS-110) in combination with OX40L (HS-130) and checkpoint inhibition are now underway, and we look forward to providing further clinical updates."

On September 2, 2020 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported that management will participate in two upcoming virtual investor conferences (Press release, Bellicum Pharmaceuticals, SEP 2, 2020, View Source [SID1234564322]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Wells Fargo 2020 Virtual Healthcare Conference
Date/Time: Wednesday, September 9, 2020 at 12:40 p.m. EDT
Format: Analyst Moderated Discussion

H.C. Wainwright 22nd Annual Global Investment Conference
Date/Time: Tuesday, September 15, 2020 at 2:30 p.m. EDT
Format: Presentation

A live webcast of the analyst moderated discussion session at Wells Fargo and the H.C. Wainwright presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

On September 2, 2020 XOMA Corporation (NASDAQ: XOMA) reported its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences (Press release, Xoma, SEP 2, 2020, View Source [SID1234564320]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference. The presentation will take place on Monday, September 14, 2020, at 2:00 PM ET.
Cantor Fitzgerald Virtual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 4:00 PM ET.
Live webcasts of each presentation can be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. Replays of both presentations will be available and archived on the site for 90 days after the event.